

CLEVELAND BIOLABS INC  
Form 8-K  
January 12, 2007

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report: (Date of earliest event reported): January 12, 2007

**CLEVELAND BIOLABS, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware  
(State or other  
jurisdiction  
of incorporation or  
organization)**

**001-12465  
(Commission File  
Number)**

**20-0077155  
(I.R.S. Employer  
Identification Number)**

**11000 Cedar Ave., Suite  
290  
(Address of principal  
executive offices)**

Registrant's telephone  
number, including area  
code: (216) 229-2251

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

“ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

**Item 1.01. Entry into a Material Definitive Agreement**

On January 12, 2007, Cleveland BioLabs, Inc. (the “Company”) entered into a Sponsored Research Agreement (the “Agreement”) with Roswell Park Cancer Institute Corporation (“Sponsor”) to develop the Company’s cancer and radio-protectant drug candidates. Among its terms, the Agreement provides that Sponsor will provide the Company with up to \$3 million of research grant funding, and the Company will establish a major research/clinical facility at Sponsor’s campus in Buffalo, New York. The Agreement also provides terms and conditions pursuant to which the Company and Sponsor may collaborate on research and clinical trials during the five-year term of the Agreement. A copy of the agreement is attached as Exhibit 10.1 and incorporated herein by reference.

**Item 8.01. Other Events**

On January 12, 2007, the Company issued a press release announcing the transaction described in Item 1.01. A copy of the press release is attached as Exhibit 99.1

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

<b>Exhibit No.</b>	<b>Exhibit</b>
10.1	Sponsored Research Agreement between Cleveland BioLabs, Inc. and Roswell Park Cancer Institute Corporation effective as of January 12, 2007.
99.1	Press Release dated January 12, 2007.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CLEVELAND BIOLABS, INC.

Date: January 12, 2007

By: /s/ Michael Fonstein  
Michael Fonstein  
President and Chief Executive  
Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Exhibit</b>
10.1	Sponsored Research Agreement between Cleveland BioLabs, Inc. and Roswell Park Cancer Institute Corporation effective as of January 12, 2007.
99.1	Press Release dated January 12, 2007.

4

---